Operator
Good day, and thank you for standing by. Welcome to Genscript 2025 Annual Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your first speaker today, Mr. Phil Zhou, CFO. Please go ahead.
Jing Zhou
Hello, everyone. This is Phil Zhou, CFO at Genscript. Welcome to 2025 Annual Results Conference Call. Joining me on the call today are Mr. Robin Meng, Chairman of the Board; Ms. Sherry Shao, Rotating CEO of Genscript; Dr. Ray Chen, President of Genscript Life Science Group; Dr. Aixi Bai, General Manager of Bestzyme; Mr. Allen Guo, CEO of ProBio.
During today’s call, we will be making statements about future expectations, plans and prospects as well as any other statements regarding matters that are not historical facts, which may constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements because of various important risk factors and the changing market conditions. We do not undertake any obligation to publicly update any forward-looking statements.
Today, Sherry will start with the company highlights and our business heads will present highlights for each segment. I will then guide you through 2025 financial performance. Following that, Sherry will update our business focus and the 2026 full year guidance. We also have a Q&A session at the end of the call. As a reminder, today’s presentation materials can be accessed in the Investor Relations section of the company’s